Patient-Derived Xenograft Model Market is expected to reach US$ 1,119.36 Million by 2031

Mice Model Segment Drives Patient-Derived Xenograft Model Market Growth

According to our new research study named "Patient-Derived Xenograft Model Market Forecast to 2031 – Global Analysis – by Type, Tumor Type, Application, End User, and Geography," the market was valued at US$ 468.75 million in 2024 and is projected to reach US$ 1,119.36 million by 2031; it is expected to register a CAGR of 13.5% during 2025–2031. The rising prevalence of cancer and growing demand for personalized medicine are key factors driving the adoption of patient-derived xenograft models. The hybrid models combining PDX with organoids and 3D cultures are projected to bring new patient-derived xenograft model market trends in the coming years.

Patient-derived xenograft (PDX) models involve implanting human tumor tissues into immunodeficient mice, preserving tumor heterogeneity and characteristics, enabling accurate preclinical evaluation of cancer biology, drug efficacy, and personalized treatment responses. Rising cancer prevalence, demand for personalized medicine, advancements in oncology research, increased funding for cancer studies, and limitations of traditional cell-line-based models are driving the global patient-derived xenograft model market growth. Apart from that, technological advances in genomic profiling and the wider use of PDX models for drug efficacy and resistance studies are also contributing to the rising patient-derived xenograft model market size.

Patient-Derived Xenograft Model Market, by Region, 2024 (%)

Source: The Insight Partners Analysis

Patient-Derived Xenograft Model Market Analysis Based on Segmental Evaluation:

Based on type, the market is bifurcated into rats model and mice model. The mice model segment held a significant patient-derived xenograft model market share in 2024. The mice model has become the leading tool in preclinical cancer research, as it most accurately reflects human tumor biology. In PDX operations, the patient's tumor pieces are put either under the skin or into the original organ of immunodeficient strains such as NOD-SCID or NSG mice. These models retain the intratumoral heterogeneity, genomic stability, and stromal architecture, which are usually the ones that get lost in cell-line xenografts with further passages. Such biological similarity—sharing over 95% genetic homology with humans—allows highly accurate prediction of therapeutic responses. Thus, the clinical trials attrition rate of 90% can be brought down significantly, as responders are identified at an early stage. For instance, Crown Bioscience's HuPrime PDX library consists of more than 4,000 models of cancers—including breast and lung—by which pharmaceutical companies such as Pfizer validate PARP inhibitors in ovarian tumors with BRCA mutations, thus accelerating approval timelines.

The mice segment growth is mainly due to increased investments in research and development of personalized medicine. These investments align with a rising trend of cancer incidences. The WHO projections indicate that there will be 20 million new cancer cases globally in 2024. The improvement of CRISPR-edited immunodeficient strains has brought about a rise in engraftment rates up to 80%. Mice models are cost-efficient, and up to 100 models per facility can be handled.  Genetic manipulations are simpler in mice. Such factors make mice models segment more popular than other ​‍​‌‍​‍‌​‍​‌‍​‍‌segments.

The geographical scope of the patient-derived xenograft model market report encompasses an assessment of the market performance in North America, Europe, Asia Pacific, South and Central America, the Middle East and Africa. North America dominated the patient-derived xenograft model market share in 2024. The​‍​‌‍​‍‌​‍​‌‍​‍‌ increasing number of cancer cases in the region has led to a higher demand for accurate preclinical models that can adequately represent human tumor biology. PDX models offer such accuracy and have become the first choice of oncology research and drug development. The market growth is also propelled by the presence of a cluster of well-established pharmaceutical and biotechnology companies, along with a robust research infrastructure and both public and private-funded initiatives. The improvements in genomics, personalized medicine, and molecular biology have extended the use of PDX models in characterizing targeted therapies and in silico prediction of patient-specific drug responses, thus boosting the patient-derived xenograft model market growth.

Furthermore, the local regulatory agencies and the research community in the US and Canada are progressively advocating the utilization of PDX models to carry out translational cancer research, thus resulting in a higher pace of adoption. The partnerships among the academic institutions, contract research organizations (CROs), and industry players are in a way that facilitate the ideation and technological breakthroughs in model creation. There is an ongoing major transition to precision oncology, and efforts are being made to reduce clinical trial failures through enhanced preclinical testing. All these factors collectively drive the market growth.

Noble Life Sciences, Charles River Laboratories International Inc, Crown Bioscience Inc, Experimental Pharmacology & Oncology Berlin-Buch GmbH, Hera BioLabs, Oncodesign Services, WuXi AppTec Co. Ltd., BioDuro LLC, XenTech SAS, and Shanghai LIDE Biotech. Co. Ltd. are among the leading companies profiled in the patient-derived xenograft model market report.

Based on type, the patient-derived xenograft model market is bifurcated into rats model and mice model. Based on tumor type, the market is classified into gastrointestinal tumor model, gynecological tumor model, respiratory tumor model, and other tumor models. By application, the market is segmented into preclinical drug development, biomarker analysis, translational research, and biobanking. In terms of end user, the market is classified into pharmaceutical and biotechnology companies, academics and research institutes, and contract research organizations. Geographically, the patient-derived xenograft model market is segmented into North America (US, Canada, and Mexico), Europe (France, Germany, UK, Spain, Italy, and the Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific), the Middle East and Africa (Saudi Arabia, South Africa, the UAE, and the Rest of the Middle East and Africa), and South and Central America (Brazil, Argentina, and the Rest of South and Central America).

Contact Us

Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com